质谱技术在浆细胞疾病患者识别与监测中的潜在作用:现状与未解问题
质谱技术较标准电泳技术能更灵敏地评估和监测副蛋白,国际骨髓瘤工作组(IMWG)近期批准完整轻链基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)替代免疫固定电泳用于临床评估和临床试验患者评估。本综述讨论了不同质谱分析方法在分析性能和实际应用方面的差异及挑战。
要点
- 质谱技术较标准电泳技术能更灵敏地检测和监测单克隆蛋白。
- IMWG近期批准完整轻链MALDI-TOF MS替代免疫固定电泳用于临床和临床试验评估。
- 完整轻链质谱可提供单克隆轻链结构信息,包括N-连接糖基化。
核心结论
- 质谱技术较标准电泳技术能更灵敏地评估和监测副蛋白,IMWG近期批准完整轻链MALDI-TOF MS替代免疫固定电泳用于临床评估和临床试验患者评估。
- 质谱检测灵敏度提高可能有助于检测和监测许多既往不可测量疾病患者的单克隆蛋白,将降低完全缓解率并增加低水平单克隆蛋白的检出。
研究设计与样本
- 本综述讨论了质谱技术在浆细胞疾病患者识别与监测中的潜在作用、不同质谱分析方法的分析与实践差异及质谱面临的挑战。
主要发现
- 质谱技术较标准电泳技术能更灵敏地评估和监测副蛋白。
- IMWG近期批准完整轻链MALDI-TOF MS替代免疫固定电泳用于临床评估和临床试验患者评估。
- 质谱检测灵敏度提高可能有助于检测和监测许多既往不可测量疾病患者的单克隆蛋白,将降低完全缓解率并增加低水平单克隆蛋白的检出。
- 追踪单克隆蛋白独特质量或氨基酸序列的能力在大多数IgG kappa骨髓瘤患者中消除了治疗性单克隆抗体的干扰。
- 完整轻链质谱可提供单克隆轻链结构信息,包括N-连接糖基化,后者在致淀粉样变性轻链上更常见,并可能在意义未明单克隆丙种球蛋白病(MGUS)中具有预后意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mass spectrometry (MS) techniques provide a highly sensitive methodology for the assessment and monitoring of paraproteins compared to standard electrophoretic techniques. The International Myeloma Working Group (IMWG) recently approved the use of intact light chain matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) in lieu of immunofixation in the clinical assessment of patients and the assessment of patients enrolled on clinical trials. The increased sensitivity of these assays may help to detect and monitor monoclonal proteins (MP) in many patients with previously non-measurable disease, will reduce complete response (CR) rates and increase detection of low-level MP. The ability to track the unique mass or amino acid sequence of the MP also eliminates interference from therapeutic monoclonal antibodies (tmAbs) in most patients with IgG kappa myeloma. The intact light chain assays also provide structural information about the monoclonal light chain, including the presence of N-linked glycosylation, which has been shown to be commoner on amyloidogenic light chains and may have prognostic significance in monoclonal gammopathy of undetermined significance (MGUS). In this review, we discuss these issues alongside differences in the analytical and practical aspects related to the different MS assays under development and the challenges for MS.
引用
- Giles HV, Wechalekar A, Pratt G, et al. The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered? Br J Haematol. 2022. PMID: 35514140. doi:10.1111/bjh.18226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。